Related references
Note: Only part of the references are listed.Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period
Evangelos Terpos et al.
ANNALS OF HEMATOLOGY (2020)
Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).
Saad Zafar Usmani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Smith Giri et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).
Parameswaran Hari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial.
Katja Weisel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.
Benjamin Avi Derman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Saad Zafar Usmani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
Pashna N. Munshi et al.
CANCER (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors A Systematic Review and Meta-analysis
Smith Giri et al.
JAMA ONCOLOGY (2020)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2019)
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review
Mohamad Mohty et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)
Murielle Roussel et al.
BLOOD (2019)
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Darrell J. White et al.
BLOOD (2019)
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Jithma P. Abeykoon et al.
BLOOD (2019)
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
Nizar Bahlis et al.
BLOOD (2019)
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Philippe Moreau et al.
BLOOD (2019)
Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial
Katja Weisel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study
Philippe Moreau et al.
BLOOD (2019)
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study
Ola Landgren et al.
BLOOD (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Luciano J. Costa et al.
BLOOD (2019)
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
L. Rasche et al.
LEUKEMIA (2019)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L. Garfall et al.
BLOOD ADVANCES (2019)
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients
Rafael Rios-Tamayo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Deepika S. Das et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Monika Engelhardt et al.
HAEMATOLOGICA (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
Luciano J. Costa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Share Paper
